Biogen Executive and Leadership Team

Christopher Viehbacher, the President & Chief Executive Officer at Biogen, directs the overarching corporate strategy and global mission to transform the landscape of neurological care. Overseeing the entire organizational structure, the President & Chief Executive Officer aligns research priorities with commercial goals to ensure sustainable growth across international markets. This leadership role involves constant engagement with the Board to refine the long-term vision for biologics and gene-based therapies. By prioritizing high-impact drug development, Christopher Viehbacher drives the company toward market leadership in treating multiple sclerosis and rare disorders. The President & Chief Executive Officer maintains a sharp focus on operational efficiency, ensuring that resources support the most promising scientific breakthroughs. Ultimately, Viehbacher secures the future of the enterprise by fostering a culture of innovation and accountability throughout the global workforce.

Andrew McKay, the Chief Financial Officer, Biogen (North America) at Biogen, directs the financial planning and fiscal health of the North American operations. Overseeing regional budget allocations, the Chief Financial Officer, Biogen (North America) ensures that capital investments align with the company's strategic focus on neurodegenerative disease research. This role involves managing complex financial reporting and risk assessment to support the commercialization of therapies across the continent. By optimizing cost structures and resource distribution, Andrew McKay drives financial discipline and operational efficiency. The Chief Financial Officer, Biogen (North America) collaborates with executive leadership to evaluate market trends and investment opportunities that bolster the regional portfolio. Through precise financial modeling and strategic oversight, McKay maintains the fiscal stability required to sustain long-term growth and innovation within the highly competitive North American pharmaceutical market.

Nicholas Colafemina, the Chief of Staff To the Chief Financial Officer. Director at Biogen, manages the strategic priorities and administrative operations for the global finance function. Overseeing the integration of financial initiatives, the Chief of Staff To the Chief Financial Officer. Director ensures that the finance department remains synchronized with the company's broader scientific and commercial objectives. This role involves facilitating high-level meetings, tracking key performance indicators, and preparing critical data for executive review. By streamlining the flow of information to the Chief Financial Officer, Nicholas Colafemina enables more effective decision-making regarding capital allocation and investment strategies. The Chief of Staff To the Chief Financial Officer. Director monitors organizational health and project timelines to ensure that financial goals are met with precision. Through diligent coordination, Colafemina supports the overall financial integrity and strategic direction of the organization.

Robin Kramer, the Executive Vice President, Chief Financial Officer at Biogen, directs the global financial strategy and capital structure of the entire organization. Overseeing treasury, accounting, and investor relations, the Executive Vice President, Chief Financial Officer ensures that the company maintains the financial strength necessary to fund advanced neuroscience research. This role involves managing global financial risks and ensuring compliance with international regulatory standards. By providing strategic financial guidance to the Board, Robin Kramer shapes the long-term investment roadmap for the company's portfolio of therapies. The Executive Vice President, Chief Financial Officer monitors global market conditions to optimize resource allocation and drive shareholder value. Through rigorous financial oversight and strategic planning, Kramer supports the company's mission to deliver innovative treatments for serious neurological diseases while maintaining a robust and sustainable balance sheet.

Takatsugu Den, the President & Managing Director at Biogen, directs the strategic operations and market growth within the Asia-Pacific region. Overseeing regional commercial activities, the President & Managing Director ensures that the company's therapies reach patients in key markets through effective local partnerships and regulatory engagement. This role involves adapting global strategies to meet the specific healthcare needs and market dynamics of the region. By fostering strong relationships with local medical institutions and government stakeholders, Takatsugu Den drives the adoption of advanced neurological treatments. The President & Managing Director monitors regional performance and identifies opportunities for expanding the company's footprint in the neuroscience sector. Through dedicated leadership and operational focus, Den ensures that the company maintains a strong competitive position and delivers consistent value across the diverse and growing Asia-Pacific healthcare landscape.

Alisha Alaimo, the President & Head of North America at Biogen, directs the commercial strategy and operational execution for the company's largest market. Overseeing the sales, marketing, and patient access teams, the President & Head of North America ensures that the company's portfolio of neurological therapies reaches the patients who need them most. This role involves driving market penetration for treatments related to multiple sclerosis and other rare disorders. By analyzing regional market trends and competitive dynamics, Alisha Alaimo optimizes the commercial approach to maximize impact and revenue. The President & Head of North America collaborates with global leadership to align regional initiatives with the company's overarching mission. Through strategic leadership and a focus on patient-centric solutions, Alaimo strengthens the company's market position and ensures the successful delivery of innovative care across North America.

Kristin Melaugh, the Chief of Staff Commercial, SYFOVRE and EMPAVELI at Biogen, manages the strategic execution of commercial initiatives for critical ophthalmology assets. Overseeing cross-functional alignment, the Chief of Staff Commercial, SYFOVRE and EMPAVELI ensures that market access and patient support programs function with maximum efficacy. This role involves coordinating between sales, marketing, and medical teams to optimize the launch and growth trajectories of specialized therapies. By streamlining internal communications and project workflows, Kristin Melaugh facilitates rapid decision-making within the commercial division. The Chief of Staff Commercial, SYFOVRE and EMPAVELI monitors performance metrics to identify opportunities for expansion in competitive therapeutic landscapes. Through rigorous oversight of operational milestones, Melaugh supports the broader goal of delivering essential treatments to patients, ensuring that commercial strategies remain agile and responsive to evolving healthcare needs.

Evelyn Reuss, the Research Chief of Staff at Biogen, directs the operational framework and strategic coordination of the global research and development division. Overseeing the alignment of scientific projects with corporate goals, the Research Chief of Staff ensures that laboratory efforts translate into viable therapeutic candidates. This role involves managing the complex interface between discovery teams and clinical development to accelerate the pipeline of gene-based therapies. By optimizing research workflows and resource management, Evelyn Reuss facilitates a more efficient path from bench to bedside. The Research Chief of Staff monitors project milestones and scientific progress to ensure that the company remains at the forefront of neuroscience innovation. Through meticulous planning and cross-departmental collaboration, Reuss supports the scientific teams in their pursuit of breakthroughs for patients with rare neurological disorders.

Daniel Quirk, the Chief Medical Officer at Biogen, directs the global medical strategy and clinical evidence generation for the company's portfolio of neurological therapies. Overseeing medical affairs and clinical safety, the Chief Medical Officer ensures that all treatments meet the highest standards of efficacy and patient care. This role involves engaging with the medical community and regulatory bodies to communicate the clinical value of the company's innovations. By leading the medical strategy for multiple sclerosis and spinal muscular atrophy treatments, Daniel Quirk drives the scientific credibility of the organization. The Chief Medical Officer monitors clinical trial data and real-world evidence to inform future development and therapeutic positioning. Through expert medical leadership, Quirk ensures that the company's scientific advancements translate into meaningful improvements in patient outcomes across global healthcare systems.

Michael Parini, the Chief Legal Officer at Biogen, directs the global legal strategy, intellectual property protection, and corporate governance framework. Overseeing the legal department, the Chief Legal Officer ensures that the company navigates complex regulatory environments while safeguarding its extensive portfolio of neuroscience patents. This role involves managing litigation, compliance programs, and strategic partnerships to mitigate risk and support business objectives. By providing counsel on international expansion and commercial agreements, Michael Parini enables the company to operate effectively across diverse global markets. The Chief Legal Officer collaborates with executive leadership to ensure that all business activities align with ethical standards and legal requirements. Through proactive legal management and strategic foresight, Parini protects the company's assets and supports the continued development of life-saving therapies for patients worldwide.